Kynuramine

Kynuramine

SCHEMBL2801613

NCCC(=O)c1ccccc1N

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
GAA P10253 1/20 0.50
ALDH1A1 P00352 10/20 0.48
HSD17B10 Q99714 8/20 0.48
CFTR P13569 1/20 0.48
KDM4E B2RXH2 6/20 0.46
TSHR P16473 2/20 0.44
HPGD P15428 5/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TP53 P04637 2/20 0.43
GLA P06280 1/20 0.43
CYP3A4 P08684 1/20 0.43
MAPK1 P28482 1/20 0.43
HIF1A Q16665 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HDAC3 O15379 2/20 0.43
HDAC1 Q13547 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Kynuramine SCHEMBL30555814 1.00 MAPT (0.50) MAPTGAAALDH1A1HSD17B10CFTR
SCHEMBL28527938 0.88 MAPT (0.47) MAPTGAAALDH1A1HSD17B10CFTR
SCHEMBL10572853 0.84 MAPT (0.52) MAPTGAAALDH1A1HSD17B10CFTR
SCHEMBL7336041 0.83 NR4A2 (0.55) MAPTGAAALDH1A1HSD17B10CFTR
SCHEMBL4230481 0.83 ALDH1A1 (0.55) MAPTGAAALDH1A1HSD17B10CFTR
SCHEMBL7797864 0.82 MAPT (0.46) MAPTGAAALDH1A1HSD17B10CFTR
SCHEMBL16431087 0.82 HDAC3 (0.53) MAPTGAAALDH1A1HSD17B10CFTR
SCHEMBL30852311 0.82 HDAC3 (0.53) MAPTGAAALDH1A1HSD17B10CFTR
SCHEMBL5415859 0.80 GAA (0.44) MAPTGAAALDH1A1HSD17B10CFTR
SCHEMBL7544320 0.80 ALDH1A1 (0.47) MAPTGAAALDH1A1HSD17B10CFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 CN claimed
US-11987560-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2024-05-21 US disclosed
EP-4286381-A2 TREATMENT OF MERKEL CELLL CARCINOMA Celgene Quanticel Research, Inc. (US) 2023-12-06 EP disclosed
EP-3496721-B1 TREATMENT OF MERKEL CELLL CARCINOMA CELGENE QUANTICEL RES INC (US) 2023-12-06 EP disclosed
EP-4257591-A2 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 Celgene Quanticel Research, Inc. (US) 2023-10-11 EP disclosed
EP-3495349-B1 (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS ORYZON GENOMICS SA (ES) 2023-06-28 EP disclosed
WO-2023090822-A1 NOVEL CANNABICHROMENIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION COMPRISING SAME FOR IMPROVING COGNITIVE FUNCTION 강원대학교 산학협력단 2023-05-25 WO disclosed
CN-116096715-A Beneficial benzothiophene compositions for mental disorders or enhancement 泰科根公司 2023-05-09 CN disclosed
EP-3511319-B1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RES INC (US) 2023-05-03 EP disclosed
EP-3080100-B1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RES INC (US) 2022-11-30 EP disclosed
EP-1644316-B1 2-AMINOBENZOYL DERIVATIVES NEURIM PHARMA 1991 (IL) 2010-03-10 EP disclosed
EP-1631548-B1 INHIBITORS OF AKT ACTIVITY MERCK & CO INC (US) 2009-10-28 EP disclosed
EP-1631548-B1 INHIBITORS OF AKT ACTIVITY MERCK & CO INC (US) 2009-10-28 EP disclosed
US-7414055-B2 Inhibitors of Akt activity MERCK & CO., INC. (US) 2008-08-19 US disclosed
US-7414055-B2 Inhibitors of Akt activity MERCK & CO., INC. (US) 2008-08-19 US disclosed
US-7414055-B2 Inhibitors of Akt activity MERCK & CO., INC. (US) 2008-08-19 US disclosed
US-20080194522-A1 Development of Fluorogenic Substrates For Monoamine Oxidases (Mao-A and Mao-B) TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE 2008-08-14 US disclosed
US-20080194522-A1 Development of Fluorogenic Substrates For Monoamine Oxidases (Mao-A and Mao-B) TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE 2008-08-14 US disclosed
WO-2008041140-A2 SUBSTITUTED ARYL-INDOLE COMPOUNDS AND THEIR KYNURENINE/KYNURAMINE-LIKE METABOLITES AS THERAPEUTIC AGENTS NEURIM PHARMACEUTICALS (1991) LTD. (US) 2008-04-10 WO disclosed
US-20060270673-A1 Inhibitors of akt activity MERCK & CO., INC. (US) 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11987560-B2 Inhibitors of lysine specific demethylase-1 KDM1B, KDM1A, KDM3A MAPT 3564/4885GAA 543/4885ALDH1A1 352/4885
US-20060270673-A1 Inhibitors of akt activity AKT1, AKT2, AKT3 MAPT 2047/4885GAA 845/4885ALDH1A1 3427/4885
US-20080194522-A1 Development of Fluorogenic Substrates For Monoamine Oxidases (Mao-A and Mao-B) MAOA, MAOB, COMT MAPT 643/4885GAA 67/4885ALDH1A1 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.